GILEAD SCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings
GILEAD SCIENCES, INC. (GILD) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-25.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 · last filed 2014-02-25
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2012-12-31 was $0.00.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2012-06-30 was -$80.11M, a 5030.03% decline year-over-year.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for the quarter ending 2012-03-31 was $40.10M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2013 was $0.00.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2012 was -$40.10M.
- GILEAD SCIENCES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, gain (loss) included in earnings for fiscal 2011 was -$6.25M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | ||||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $0.00 derived: sum of 2 quarters · filed 2014-02-25 | -$80.11M derived: sum of 3 quarters · filed 2014-02-25 | -$40.10M 10-K · filed 2014-02-25 | $40.10M 10-K · filed 2013-02-27 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-06 | -$80.11M derived: sum of 2 quarters · filed 2012-11-06 | -$40.10M 10-Q · filed 2012-11-06 | -$50.84M derived: sum of 4 quarters · filed 2013-05-08 | |
| 2012-06-30 | -$80.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$40.01M 10-Q · filed 2012-08-01 | -$50.84M derived: sum of 3 quarters · filed 2013-05-08 | -$49.13M derived: sum of 4 quarters · filed 2013-05-08 | |
| 2012-03-31 | $40.10M 10-Q · filed 2013-05-08 | $29.27M derived: sum of 2 quarters · filed 2013-05-08 | $30.98M derived: sum of 3 quarters · filed 2013-05-08 | $32.60M derived: sum of 4 quarters · filed 2013-05-08 | |
| 2011-12-31 | -$10.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | -$9.12M derived: sum of 2 quarters · filed 2013-02-27 | -$7.50M derived: sum of 3 quarters · filed 2013-02-27 | -$6.25M 10-K · filed 2013-02-27 | |
| 2011-09-30 | $1.71M 10-Q · filed 2012-11-06 | $3.33M derived: sum of 2 quarters · filed 2012-11-06 | $4.58M 10-Q · filed 2012-11-06 | ||
| 2011-06-30 | $1.63M 10-Q · filed 2012-08-01 | $2.87M 10-Q · filed 2012-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |